FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563485399> ?p ?o ?g. }

• W2563485399 abstract "Numerous studies have demonstrated an inverse relationship between circulating Vitamin D levels and risk of colorectal cancer. Although calcitriol, the most active form of Vitamin D3, exhibits promising antitumorigenic activity, its use as a chemopreventive agent has been restricted by its hypercalcemic effect at therapeutic doses. Eldecalcitol (1α,25-dihydroxy-2β-(3-hydroxypropyloxy) Vitamin D3 or ED-71), a novel analog of calcitriol, is more potent than calcitriol in stimulating bone modeling and is approved for the treatment of osteoporosis in Japan. The goal of the present study was to assess the activity of ED-71 against colorectal adenomas in a unique mouse model of spontaneous multiple intestinal neoplasia (Apc+/Min-FCCC mice). In a preliminary dose-finding study, male Apc+/Min-FCCC mice (6 weeks old, 6-7/group) were treated with vehicle (medium chain triglyceride (MCT)), calcitriol (0.25 μg/kg body weight (bw)), or ED-71 (0.2, 0.1, 0.05, 0.025, 0.0125 μg/kg bw) every other day by gavage for 6 weeks. Body weight was recorded weekly and mice were euthanized at the end of the study. ED-71 was well tolerated at all doses tested, with no significant difference in body weight observed in treated animals as compared to controls. Drug toxicity was assessed by measuring serum calcium levels by colorimetric assay (BioVision Inc.) and hepatic alkaline phosphatase (ALP) by ELISA (Antibodies-online.com). No significant effect of ED-71 on serum calcium levels and hepatic ALP activity was observed. However, because some concern exists regarding the ability of mice treated with high-dose ED-71 (0.2 μg/kg bw) to maintain their body weight long-term, ED-71 doses of 0.05 and 0.1 μg/kg bw were selected for the long-term efficacy study. Prior to entry on this study, male Apc+/Min-FCCC mice (6 weeks old) were prescreened endoscopically to determine tumor-bearing status. Mice were randomized based on tumor status (tumor-free or tumor-bearing) and body weight to one of four treatment groups: vehicle (MCT), calcitriol (0.25 μg/kg bw), ED-71 (0.05 μg/kg bw) or ED-71 (0.1 μg/kg bw). Drugs were administered by gavage every other day for 14 weeks. At the end of the study, intestinal tissue was examined grossly and tumor multiplicity was recorded. No significant effect of ED-71 on tumor multiplicity was observed in tumor-bearing mice. However, in tumor-free mice (11-13/group), treatment with ED-71 (0.1 μg/kg bw) reduced the incidence of gross tumors by 36% (P = 0.017) and colon tumor multiplicity by 30% as compared to that of controls (63.6% vs. 100%, 1.4 ± 0.4 vs. 2.0 ± 0.4, respectively). These findings suggest that ED-71 is effective in inhibiting colon tumorigenesis when given to mice prior to tumor formation. These promising data provide support for future studies to determine the potential utility of ED-71 for the prevention of colorectal cancer in high-risk subjects. (Supported by NCI HHSN261201200015I) Citation Format: Wen-Chi L. Chang, Esther Kaunga, Harry S. Cooper, Lisa Vanderveer, Jing Peng, Yongchao Zhang, Chen S. Suen, Margie L. Clapper. Effect of ED-71, an analogue of Vitamin D3, on intestinal neoplasia in the Apc+/Min-FCCC mouse model. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2806. doi:10.1158/1538-7445.AM2015-2806" @default.
• W2563485399 created "2017-01-06" @default.
• W2563485399 creator A5006292933 @default.
• W2563485399 creator A5022569332 @default.
• W2563485399 creator A5033708735 @default.
• W2563485399 creator A5038577843 @default.
• W2563485399 creator A5041617519 @default.
• W2563485399 creator A5045149885 @default.
• W2563485399 creator A5067104727 @default.
• W2563485399 creator A5090126068 @default.
• W2563485399 date "2015-08-01" @default.
• W2563485399 modified "2023-09-27" @default.
• W2563485399 title "Abstract 2806: Effect of ED-71, an analogue of Vitamin D3, on intestinal neoplasia in the Apc+/Min-FCCC mouse model" @default.
• W2563485399 doi "https://doi.org/10.1158/1538-7445.am2015-2806" @default.
• W2563485399 hasPublicationYear "2015" @default.
• W2563485399 type Work @default.
• W2563485399 sameAs 2563485399 @default.
• W2563485399 citedByCount "0" @default.
• W2563485399 crossrefType "proceedings-article" @default.
• W2563485399 hasAuthorship W2563485399A5006292933 @default.
• W2563485399 hasAuthorship W2563485399A5022569332 @default.
• W2563485399 hasAuthorship W2563485399A5033708735 @default.
• W2563485399 hasAuthorship W2563485399A5038577843 @default.
• W2563485399 hasAuthorship W2563485399A5041617519 @default.
• W2563485399 hasAuthorship W2563485399A5045149885 @default.
• W2563485399 hasAuthorship W2563485399A5067104727 @default.
• W2563485399 hasAuthorship W2563485399A5090126068 @default.
• W2563485399 hasConcept C121608353 @default.
• W2563485399 hasConcept C124490489 @default.
• W2563485399 hasConcept C126322002 @default.
• W2563485399 hasConcept C134018914 @default.
• W2563485399 hasConcept C160160445 @default.
• W2563485399 hasConcept C181199279 @default.
• W2563485399 hasConcept C185592680 @default.
• W2563485399 hasConcept C2776079296 @default.
• W2563485399 hasConcept C2776940978 @default.
• W2563485399 hasConcept C29730261 @default.
• W2563485399 hasConcept C519063684 @default.
• W2563485399 hasConcept C526805850 @default.
• W2563485399 hasConcept C55493867 @default.
• W2563485399 hasConcept C71924100 @default.
• W2563485399 hasConceptScore W2563485399C121608353 @default.
• W2563485399 hasConceptScore W2563485399C124490489 @default.
• W2563485399 hasConceptScore W2563485399C126322002 @default.
• W2563485399 hasConceptScore W2563485399C134018914 @default.
• W2563485399 hasConceptScore W2563485399C160160445 @default.
• W2563485399 hasConceptScore W2563485399C181199279 @default.
• W2563485399 hasConceptScore W2563485399C185592680 @default.
• W2563485399 hasConceptScore W2563485399C2776079296 @default.
• W2563485399 hasConceptScore W2563485399C2776940978 @default.
• W2563485399 hasConceptScore W2563485399C29730261 @default.
• W2563485399 hasConceptScore W2563485399C519063684 @default.
• W2563485399 hasConceptScore W2563485399C526805850 @default.
• W2563485399 hasConceptScore W2563485399C55493867 @default.
• W2563485399 hasConceptScore W2563485399C71924100 @default.
• W2563485399 hasLocation W25634853991 @default.
• W2563485399 hasOpenAccess W2563485399 @default.
• W2563485399 hasPrimaryLocation W25634853991 @default.
• W2563485399 hasRelatedWork W1443108546 @default.
• W2563485399 hasRelatedWork W1483779827 @default.
• W2563485399 hasRelatedWork W1976144347 @default.
• W2563485399 hasRelatedWork W200085739 @default.
• W2563485399 hasRelatedWork W2024266842 @default.
• W2563485399 hasRelatedWork W2060063916 @default.
• W2563485399 hasRelatedWork W2113669808 @default.
• W2563485399 hasRelatedWork W2329168266 @default.
• W2563485399 hasRelatedWork W2339915984 @default.
• W2563485399 hasRelatedWork W2357355043 @default.
• W2563485399 hasRelatedWork W2358654987 @default.
• W2563485399 hasRelatedWork W2362991021 @default.
• W2563485399 hasRelatedWork W2366468656 @default.
• W2563485399 hasRelatedWork W2376365909 @default.
• W2563485399 hasRelatedWork W2376976586 @default.
• W2563485399 hasRelatedWork W2388342914 @default.
• W2563485399 hasRelatedWork W2404733004 @default.
• W2563485399 hasRelatedWork W2489910896 @default.
• W2563485399 hasRelatedWork W2978553166 @default.
• W2563485399 hasRelatedWork W3080706624 @default.
• W2563485399 isParatext "false" @default.
• W2563485399 isRetracted "false" @default.
• W2563485399 magId "2563485399" @default.
• W2563485399 workType "article" @default.